J. Matthew Singleton, Director at Viking Therapeutics, Inc. (VKTX), sold 29,500 shares at $64.88 ($1.8M) on 2024-08-19, disclosed to the SEC on 2024-08-19.
Scheduled sale ($1.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.01 | 2,500 | $150K | 8.1% |
| 2 | $61.13 | 3,047 | $186K | 10.1% |
| 3 | $61.13 | 3,047 | $186K | 10.1% |
| 4 | $61.86 | 4,509 | $279K | 15.2% |
| 5 | $61.86 | 4,509 | $279K | 15.2% |
| 6 | $63.15 | 2,055 |
| $130K |
| 7.0% |
| 7 | $63.15 | 2,055 | $130K | 7.0% |
| 8 | $64.10 | 2,388 | $153K | 8.3% |
| 9 | $64.10 | 2,388 | $153K | 8.3% |
| 10 | $64.88 | 1,501 | $97K | 5.3% |
| 11 | $64.88 | 1,501 | $97K | 5.3% |
| Total | $62.40 avg | 29,500 | $1.8M | 100% |
| Filing → |
| VKTX | SELL | 2024-08-22 | $397K | — | Filing → |
| VKTX | SELL | 2024-08-14 | $2.4M | — | Filing → |
| VKTX | BUY | 2018-05-31 | $93K | — | Filing → |